HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.

IF 20.1 1区医学 Q1 ONCOLOGY

Cancer Communications Pub Date : 2025-01-06 DOI:10.1002/cac2.12657

Christian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, Ulrike Maria Heber, Charlotte Mang-Manger, Daniel Egle, Marija Balic, Angelika Pichler, Georg Pfeiler, Stephanie Kacerovsky-Strobl, Christoph Suppan, Magdalena Ritter, Edgar Petru, Richard Greil, Zsuzsanna Bago-Horvath, Christine Deutschmann, Günther Georg Steger, Michael Seifert, Florian Fitzal, Rupert Bartsch, Anu Santhanagopal, Jana Machacek-Link, Dalila Sellami, Magdalena Schwarz, Christian Fesl, Lidija Sölkner, Stephen Esker, Martin Filipits, Michael Gnant

引用次数: 0

查看原文本刊更多论文

HER2阴性早期乳腺癌新辅助治疗期间HER2和HER3的表达：生物标志物驱动的T-DXd和HER3- dxd测序的潜力

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

25.50

自引率

4.30%

发文量

153

审稿时长

4 weeks

期刊介绍： Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.